Skip to main content
. 2022 Jan 4;15(1):41–51. doi: 10.1007/s12328-021-01567-4

Fig. 2.

Fig. 2

Distribution mapping of serum IgM-free AIM level in non-HCC (hepatitis and cirrhosis) and HCC patient groups for all cancer stages. The results are shown in ad are for all cancer stages of NASH-HCC, HBV-HCC, HCV-HCC, and all the patients, respectively. The serum IgM-free AIM level was significantly higher in the HCC patient group than that in the non-HCC patient group (p < 0.001) regardless of the pathogenesis. *p < 0.001 (Mann–Whitney U-test). AIM apoptosis inhibitor of macrophage, HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, NASH non-alcoholic steatohepatitis